- $121.93bn
- $140.83bn
- £32.67bn
- 98
- 63
- 99
- 99
REG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Change of Registered Office
AnnouncementREG - GSK PLC - Update on phase I/II therapeutic HSV vaccine trial
AnnouncementREG - GSK PLC - Depemokimab late-breaking data presented at ERS
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive Phase III results for Nucala in COPD
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - EMA approval on Arexvy for 50-59 at risk
AnnouncementREG - GSK PLC - Nucala approved in Japan for use in CRSwNP
AnnouncementREG - GSK PLC - SENKU Designation for Bepirovirsen in Japan
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - B7-H3 ADC US FDA Breakthrough Therapy Designation
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
Announcement